Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | PER2 | O15055 | 1/20 | 0.32 |
| ▸ | CRY1 | Q16526 | 1/20 | 0.32 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3674271 | 1.00 | MDM2 (0.33) | MDM2TP53BACE1PER2CRY1 | |
| SCHEMBL3667708 | 0.85 | HRH4 (0.33) | BACE1 | |
| SCHEMBL3666328 | 0.84 | BACE1 (0.36) | BACE1 | |
| SCHEMBL13007684 | 0.83 | BACE1 (0.34) | MDM2TP53BACE1HCRTR2 | |
| SCHEMBL3668395 | 0.83 | BACE1 (0.34) | MDM2TP53BACE1HCRTR2 | |
| SCHEMBL3672320 | 0.83 | BACE1 (0.35) | BACE1 | |
| SCHEMBL3667642 | 0.82 | BACE1 (0.31) | BACE1 | |
| SCHEMBL3669875 | 0.81 | BACE1 (0.30) | BACE1 | |
| SCHEMBL3669278 | 0.81 | HRH4 (0.32) | BACE1HCRTR2 | |
| SCHEMBL13007631 | 0.81 | HRH4 (0.32) | BACE1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851484-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2010-12-14 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | TNNC1, TNNI3, TNNT2 | MDM2 2864/4885TP53 723/4885BACE1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.